Overview

Switch Maintenance in Pancreatic

Status:
Not yet recruiting

Trial end date:
2028-09-30

Target enrollment:

Participant gender:

Summary

This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body. This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells. The names of the study drugs involved in this study are: - Domvanalimab (also known as AB154) - Zimberelimab (also known as AB122) - APX005M

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

James Cleary, MD, PhD

Collaborators:

Arcus Biosciences, Inc.
Lustgarten Foundation